News | March 13, 2021
AstraZeneca Pharma India receives approval for supplying Osimertinib in India
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Combination shows consistent benefit across prespecified post-progression outcomes
The company has received five final approvals
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Subscribe To Our Newsletter & Stay Updated
